Treatment of dihydromyricetin (DHM) can inhibit HSC activation in vitro and decrease CCl4-induced liver fibrosis in C57BL/6 mice by improving NK cell killing ability and IFN-γ expression through the NF-κB/STAT3 pathway. This evidence concerns the gene STAT3 and Hepatic fibrosis.